The HYI Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung adenocarcinoma cell line NCI-H1975, designed to disrupt the endogenous HYI gene. This polyclonal pool, generated through Cas9-mediated genome editing, introduces loss-of-function mutations across the cell population, providing a heterogeneous model for studying HYI-dependent metabolic processes. The product circumvents clonal selection artifacts and offers a physiologically diverse representation of the knockout phenotype, making it suitable for bulk functional assays in non-small cell lung cancer (NSCLC) research.
The NCI-H1975 host cell line is a well-characterized human lung adenocarcinoma model derived from a malignant epithelial tumor, expressing wild-type EGFR, and is widely employed in NSCLC biomedical studies. These adherent epithelial cells exhibit classical adenocarcinoma features and have been instrumental in exploring oncogenic signaling, drug resistance, and metabolic reprogramming. Their genetic and phenotypic stability renders them an ideal chassis for interrogating the consequences of HYI loss in a clinically relevant lung cancer context.
HYI encodes a hydroxypyruvate isomerase that catalyzes the conversion of hydroxypyruvate to 2-hydroxy-3-oxopropanoate, a critical step at the intersection of glyoxylate detoxification and carbohydrate metabolism. The enzyme is transcriptionally regulated by HIF1A and PPARGC1A in response to glucose availability and nutritional stress, and it directly modulates levels of glyoxylate, oxalate, serine, and glycine. HYI physically and functionally interacts with GRHPR, AGXT, LDHA, and PKM2, linking hydroxypyruvate metabolism to glyoxylate clearance, lactate dehydrogenase activity, and glycolytic flux. In the broader metabolic network, HYI operates in concert with GRHPR, AGXT, LDHA, GOT1, PSAT1, and PSPH to maintain serine homeostasis and manage reactive aldehyde species, thereby supporting cellular biosynthetic and redox needs.
Disruption of HYI in NCI-H1975 cells is anticipated to impair glyoxylate metabolism, leading to elevated hydroxypyruvate and glyoxylate levels, increased oxalate production, and disrupted serine/glycine synthesis. These metabolic derangements can induce oxalate stress and compromise the ability of lung adenocarcinoma cells to cope with nutritional deprivation, a hallmark of the tumor microenvironment. Consequently, the polyclonal knockout model provides a powerful tool to dissect the reliance of NSCLC on HYI-driven pathways for proliferation, survival, and adaptation to serine/glycine-limited conditions, potentially uncovering targetable metabolic liabilities.
Key experimental applications include LC-MS-based metabolomic profiling to quantify hydroxypyruvate and glyoxylate pools, 13C-glucose isotopic tracing to map carbon flux through serine biosynthesis, and Seahorse extracellular flux assays to measure glycolytic and mitochondrial respiration. Researchers can further assess cellular viability and clonogenic potential under serine and glycine starvation, perform oxalate quantification to evaluate detoxification capacity, and use Western blotting to confirm HYI disruption and monitor expression changes in GRHPR, AGXT, and LDHA. For additional guidance on integrating these HYI knockout polyclonal cells into your metabolic oncology studies, contact Ascent Research.
